Symposium reveals insights on immunotherapy and targeted treatment in advanced endometrial cancer, suggesting improved patient selection.
According to USA data, around 15% of patients with endometrial cancer (EC) have advanced disease at diagnosis, which is associated with poor survival rates and a high risk of recurrence. This symposium explored treatment strategies in advanced EC (aEC), focusing on the key role of immunotherapy in combination with targeted treatment such as the tyrosine kinase inhibitor (TKI), levatinib. Experts provided important real-world insights into treatment decision-making and the management of adverse events in order to optimise outcomes for patients.
No takes yet. Share an insight, caveat, or question.
Helen Boreham (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: